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€ 617, € 65, € 1.707 and € 145 per patient, respectively. Budget impact analysis based on 
projected market shares of FF/VI, FP/S, and BUD/F revealed that introduction of FF/VI 
could save the national Sick Fund € 711,000 in the first three years. ConClusions: 
This model predicts that the introduction of FF/VI, a once daily FDC ICS/LABA, would 
reduce the overall costs of COPD treatment in Slovenia.
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objeCtives: It is estimated that the prevalence of moderate-to-severe SA (apnoea-
hypopnoea index > 15/h) is 10%. Approximately 11% of SA patients have comorbid 
COPD, which worsens sleep quality and desaturations. This study investigated the 
effects of PAP therapy on all-cause mortality and cost of illness (COI) in patients 
with SA and COPD in Germany. A statutory health insurance (SHI) perspective was 
taken. Methods: A total of > 4 million individuals covered by the SHI database 
were analysed (≈5% of the German SHI population). PAP therapy was initiated in 
4,068 patients with SA (PAP group). Propensity score matching was used to define a 
control group (CG) of 4,068 SA patients matched for age, sex, risk factors/aetiology, 
region and medication who received usual care (no PAP). Of these, 1,300 patients 
in the PAP group and 1,192 patients in the CG had comorbid COPD. This subgroup 
of patients was followed for 3 years after initiation of PAP therapy. Results: Total 
COI was higher in the PAP group versus CG in the first year of follow-up (€ 8,697 
vs € 6,999, p< 0.0001). However, during the second and third year the difference 
in COI between the PAP and CG was smaller (year 2: € 7,340 vs € 7,316, p< 0.0048; 
year 3: € 6,847 vs € 6,714, p< 0.001). PAP recipients had a significantly lower 3-year 
mortality rate compared with CG (8.2% vs 11.7%, p< 0.001; relative risk reduction 
30.1%). ConClusions: SA patients with COPD treated with PAP showed signifi-
cantly reduced mortality and morbidity. Total COI was higher in PAP recipients 
versus CG over the first 3 years of follow-up, but the difference between groups 
decreased over time. A follow-up period of ≥ 5 years may be required to show ben-
eficial economic outcomes in SA patients receiving PAP therapy.
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objeCtives: In the US, more than half of patients with idiopathic pulmonary fibro-
sis (IPF) are covered by Medicare; yet published data on the economic burden that IPF 
imposes to this largest US payer are limited. The objective of this study was to com-
pare health care resource utilization (HRU) and costs between Medicare beneficiaries 
with IPF and matched non-IPF controls. Methods: Administrative claims from a 
5% random sample of Medicare beneficiaries (aged 65+) from years 2000 to 2011 
were analyzed. Incident IPF patients were identified based on ICD9-CM diagnosis 
codes, with at least one year enrollment before (pre-index) and after (post-index) 
the first diagnosis (index date). Up to 5 beneficiaries without IPF were matched to 
each IPF patient, based on age, gender, race, and region. Annual HRU and medical 
costs (excluding outpatient drug costs) during the pre-index and post-index peri-
ods were compared between IPF patients and the matched controls and univariate 
descriptive analyses were performed to compare the differences. Results: A total 
of 7,855 IPF patients were matched to 38,856 controls. During pre-index period, IPF 
patients had 2-3 folds higher risk of COPD, asthma and lung infections, 80% higher 
risk of hospitalization (28.8% vs. 15.8%), and higher total medical costs ($10,124 vs. 
$5,888) than matched controls (all p< 0.05). During post-index period, IPF patients 
had a higher risk of hospitalization (48.7% vs. 20.8%) and all other types of HRU 
with the total medical costs $11,955 higher than controls ($20,887 vs. $8,932) (all 
p< 0.05). Inpatient care accounted for 50% of total medical costs of IPF patients in 
both pre-index and post-index periods. ConClusions: In the US, IPF patients aged 
65 or older had a greater burden of comorbidity and incurred more HRU and medical 
costs than matched controls. Multidisciplinary team based approach and effective 
therapies are needed given the high unmet needs.
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objeCtives: To examine the economic burden and health care utilizations of 
patients diagnosed with chronic obstructive pulmonary disease (COPD) within the 
U. S. Medicare population. Methods: Patients diagnosed with COPD (International 
Classification of Disease 9th Revision Clinical Modification [ICD-9-CM] codes: 491, 
492, 496) were identified using the U. S. national Medicare claims dataset from 
01JAN2009 to 31DEC2011. The first diagnosis date was defined as the index date. A 
comparator group was created by identifying patients without a COPD diagnosis 
but of similar age, region, gender, index year and baseline Charlson Comorbidity 
Index scores. The index date for the comparator group was randomly chosen to 
reduce selection bias. One-year pre- and post-index continuous health plan enroll-
ment was required for both groups. A 1: 1 propensity score matching was used 
to compare follow-up health care costs and utilizations between the COPD and 
comparison cohorts, adjusted for baseline demographic and clinical characteris-
tics. Results: A total of 422,024 patients were identified for the COPD and compari-
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objeCtives: This study aimed to evaluate the economic burden of hospi-
talized pneumonia and its associated costs in the Brazilian Private Health 
System. Methods: An administrative claims database containing over 18 million 
lives was used to identify hospitalized pneumonia episodes, in all ages, between 
Oct/2010 and Dec/2013. Pneumonia episodes were identified using ICD-10 codes 
of A40.3, B95.3, G00.1, J13, J15, J15.0, J15.3, J15.4, J15.8, J15.9, J18, J18.0, J18.9, J20.2, 
P23.3. Pneumonia costs included were taxes and exchange, medicines, materials, 
medicinal gases, food, medical fees, exams, procedures and personal hygiene. The 
costs represent a total in the evaluated period for all causes and considering the 
total patients identified, average cost was calculated. Results: A total of 16,227 
pneumonia patients were identified with a total of 17,781 hospitalizations, repre-
senting an average of 1.1 hospitalizations per pneumonia patient in all ages. The 
aggregate costs for all inpatient treatment were BRL202,687,872.71 representing 
a total of 130,406 hospital days across the pneumonia patients. The average days 
for hospitalization per patient is 7.5 days. The average expenditure for the health 
insurance provider represents BRL12,490.78 per patient or BRL11,399.13, when 
evaluating per hospitalization. This translates to an average daily expenditure of 
BRL1,704.06 per patient or BRL1,555.13 per hospitalization. ConClusions: Costs 
related to pneumonia hospitalization are high and represents a large impact to 
the total budget spends in the private health care system. Given the significant 
economic burden associated with pneumonia, there is a need to better implement 
prevention strategies such as flu and pneumococcal vaccinations and smoking 
cessation.
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objeCtives: To compare the expected costs and outcomes associated with the 
novel once-daily fixed-dose combination (FDC) of inhaled corticosteroid (ICS) and 
long-acting beta agonist (LABA) fluticasone furoate/vilanterol (FF/VI) against those 
expected with currently available FDC options, fluticasone propionate/salmeterol 
(FP/S), budesonide/formoterol (BUD/F) and beclometasone dipropionate/formoterol 
(BD/F), for asthma treatment in Slovenia. Methods: We developed a Markov model 
based on the results of seminal study GOAL (Gaining Optimal Asthma Control) that 
takes into account the complexity of asthma treatment and particularly accompa-
nying dose titration. Using available clinical evidence, we assumed that the clini-
cal efficacy and incidence of adverse events associated with a all four FDCs were 
similar. We compared FF/VI with other FDCs of ICS/LABA from the Slovenian payers’ 
perspective at the price levels determined by international reference pricing as of 
April 2014. We followed a cohort of 12,300 asthma patients over the time horizon of 
3 years with costs and outcoumes discounted at 3.5% per annum. Results: Model 
analysis showed that the expected three-year costs of FF/VI were lower than those 
of FP/S, BUD/F and BD/F by 13%, 40%, and 32%, respectively. The costs of treatment 
with FF/VI were lower than all other FDCs of ICS/LABA for patients who were previ-
ously treated with low/medium doses of ICSs (≤ 500 mg equivalent dose of BD) or 
high-doses of ICSs (> 500 mg and ≤ 1000 mg equivalent dose of BD). Budget impact 
analysis that was based on the current ICS/LABA market and projected market 
shares of FF/VI, FP/S, and BUD/F revealed that introduction of FF/VI could save 
the national Sick Fund € 863,000 over the first three years of use. ConClusions: 
Results of our model indicate that the introduction of the new once-daily FDC ICS/
LABA FF/VI could reduce the costs of asthma treatment in Slovenia over the first 
three years after introduction.
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objeCtives: To compare expected costs and health outcomes of the novel fixed-
dose combination (FDC) of inhaled corticosteroid (ICS) and long-acting beta agonist 
(LABA) fluticasone furoate/vilanterol (FF/VI) with currently available FDC options, 
fluticasone propionate/salmeterol (FP/S) and budesonide/formoterol (BUD/F), for 
chronic obstructive pulmonary disease (COPD) treatment in Slovenia. Methods: 
We developed a population-level Markov model based on the results of seminal 
TORCH (Towards a Revolution in COPD Health) study that accounts for disease 
progression of COPD and particularly the effects of changes in lung function and 
exacerbations. Using available clinical evidence, we assumed that all FDCs of ICS/
LABA were clinically equivalent. We compared FF/VI with two other FDCs of ICS/
LABA from the payers’ perspective at the Slovenian price levels determined by 
international reference pricing as of April 2014. We followed a cohort of 8,100 
Slovenian COPD patients for 20 years, with costs and outcomes discounted at 3.5% 
per annum. Results: The life expectancy predicted by the model was 8.74 years 
with 2.76 years spent in moderate COPD, 2.55 years in severe COPD, and 3.43 in 
very severe COPD. Model analysis showed that the expected three-year survival 
of the cohort was 91% and that the expected corresponding costs of FF/VI (€ 1.021 
per patient) were lower than those of FP/S (€ 1.535 per patient; +33% vs. FF/VI) and 
BUD/F (€ 1.260 per patient; +19% vs. FF/VI). Expected costs of maintenance, moderate 
exacerbations, severe exacerbations, and pneumonia were, for all treatment choices, 
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for moderate-risk RR2378 ($75) for all ages. Average reimbursement rate was RR2,000 
($63) per outpatient episode. The average cost of hospitalization was RR20,870 ($655/
n= 500), RR20,925 ($657/n= 125) for low-risk, RR20,947 ($657/n= 364) for moderate-
risk, and RR17,684 ($554/n= 11) for high-risk patients; with 60%-80% of patients 
with CAP hospitalized and the estimated number of CAP patients of age 50 and 
older in Tver 3,249, the annual cost of CAP to payer is RR53,448,423 (~$1.7million); 
the national estimates of cost of CAP in senior adults was $124million. Employed 
patients comprise 12.8% and 18.3% among the inpatient and outpatient cases, 
respectively, and days lost from work per employed patient was 8.0 (inpatient) and 
7.0 (outpatient). ConClusions: CAP in adults is a significant cause of resource use 
and health care cost in Russia, inpatient care constitutes the majority of cost. Cost 
of treatment was similar across all age and risk groups.
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objeCtives: The aim of this study is to investigate the medical costs of COPD 
patients in South Korea. Methods: We enrolled 300 COPD patients who had been 
treated and followed up for more than one year in the three hospitals from 2012 
to 2013. The hospital electronic database was used to obtain medical costs and the 
medical records were reviewed by physicians (respiratory specialists) to assess clini-
cal characteristics. We calculated annual maintenance costs per-patient according 
to disease severity, except the costs which were related to COPD exacerbation. The 
costs of COPD exacerbation per-case was calculated and divided into severe-exac-
erbation (hospitalization and emergency visit) costs and non-severe-exacerbation 
(outpatient visit) costs. Results: The annual maintenance costs per-patient was 
KRW 351,599, KRW 401,068, KRW 573,010 and KRW 999,506 for mild, moderate, 
severe and very-severe according to GOLD criterion, respectively. In case of the 
COPD exacerbation, the costs per-case for each non-severe exacerbation and severe-
exacerbation was KRW 163,495 and KRW 2,765,086. ConClusions: The severity of 
disease and exacerbation of COPD have a substantial impact on the medical costs of 
COPD patients. Improvement of lung function and reduction of occurrence of COPD 
exacerbation will be beneficial for the reduction of the health care expenditures.
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objeCtives: Asthma is one of the mostly seen chronic illnesses in Turkey, yet there 
are limited studies on cost of asthma in our country. In addition they were based on 
a central database and weight of disease. The aim of this study was estimating the 
nationwide cost of managing asthma and examining its variability depending on 
asthma control level. Methods: The clinical pathway for asthma was determined 
from the literature. Part of the data was collected from the expert’s clinical view. To 
calculate the direct costs, the medical management of adult asthma was estimated 
using ‘cost-of-illness’ methodology for one year per patient. All costs were calcu-
lated according to payer perspective. The costs covered were pyhsician visits, hos-
pitalizations, diagnostic tests, medicine and comorbid disease. Results: According 
to recent studies, the percentage of controlled, partially controlled and uncontrolled 
patients were 22%, 50%, and %28 respectively in Turkey. The cost of asthma calcula-
tion was based on weighted percentage of control. The mean annual cost per patient 
with controlled asthma was € 558,41, partially controlled asthma was € 594,86 and 
uncontrolled asthma was € 1040,63. Hospitalizations, physician visits, diagnostic 
tests, comorbidity and medication costs were estimated to be 4%, 11%, 11%, 28%, 
46% for controlled patient, 10%, 11%, 10%, 43%, 26% for partially controlled patient 
and 48%, 6%, 6%, 25%, 15% for uncontrolled patient respectively. ConClusions: 
The cost of adult asthma in Turkey is very high and it significantly depends on 
disease control level. As expected, uncontrolled patient’s cost is higher than that 
of controlled patient. Nationwide health policies such as education of patients and 
physicians, selecting the right treatment and smoking cessation strategies that 
target the effective control of asthma will play an important role in the reduction 
of the economic burden of disease.
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objeCtives: COPD is one of the leading causes of morbidity and mortality world-
wide and has a major burden on Russian’s health care system. It’s lead to frequent 
use of health care resources. The main aim of this study was to describe the direct 
costs for management of COPD patients with differing degrees of disease sever-
ity. Methods: The methodology for cost of illness analysis was based on a previ-
ous Russian study (Avksenteva M. V. et al., 2010). One-year costs were identified by 
applying cost data to medical information obtained by medical statistical records 
from 2007. In this study were performed 2 variants of COPD costs. In 1st variant were 
used epidemiological data from 2007 and medical resources costs from 2014. In 2nd 
variant were used extrapolated epidemiological data and medical resources costs 
from 2014. Due to lack of actual data in this study was modeled situation – from 2007 
to 2012 the overall incidence of adult increased by 12.5%. Medical resources included 
hospital stays, outpatient visits and ambulance service. Results: The mean annual 
overall direct health care cost for 1st variant was estimated to be 54.6 billion rubles 
($1.6 billion), for 2nd variant was estimated to be 61.6 billion rubles ($1.8 billion). The 
son cohorts. After applying a 1: 1 matching, a total of 123,356 patients were matched 
from each cohort, with well-balanced baseline characteristics. COPD patients had 
higher health care utilization, including Medicare carrier (98.1% vs. 70.1%), Durable 
Medical Equipment (DME, 37.4% vs. 15.8%) and Home Health Agency (HHA, 17.2% 
vs. 4.6%) claims, outpatient visits (73.9% vs. 41.7%) and inpatient (32.5% vs. 6.8%), 
skilled nursing facility (SNF, 10.0% vs. 2.2%) and hospice admissions (1.2% vs. 0.6%) 
and prescription drug claims (53.4% vs. 49.8%), resulting in higher health care costs 
for Medicare carrier ($3,391 vs. $1,313), DME ($413 vs. $97), HHA ($923 vs. $228), 
outpatient ($10,110 vs. $3,514), inpatient ($5,983 vs. 1,045), SNF ($1,982 vs. $368), 
hospice ($304 vs. $143), pharmacy ($1,180 vs. $692) and total costs ($24,288 vs. $7,399) 
(p< 0.0001). ConClusions: COPD patients are associated with high economic bur-
den and health care utilization.
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objeCtives: Asthma is the most common chronic disease in childhood, reduces 
the quality of life of children and their families, and produces high social and 
health care costs. The aim of this study was to estimate the direct cost of pediat-
ric asthma in Turkey and to examine its variability depending on asthma control 
level. Methods: The clinical pathway for childhood asthma was designed by and 
based on the data from the available Turkish literature. Unavailable data was col-
lected by the expert’s clinical view. To calculate direct costs, the medical manage-
ment of childhood asthma estimated using ‘cost-of-illness’ methodology for one 
year per child. All costs were calculated from the health care payer perspective. The 
costs were covered hospitalizations, physician visits, diagnostic tests, medications 
and co morbid diseases. Results: According to the recent studies, the controlled 
patient was 60%, partial controlled patient was 25%, and uncontrolled patient was 
15% in Turkey. The cost of asthma calculation was based on weight of control. The 
mean annual cost per patient with controlled asthma is 542.97€ , partial controlled 
asthma 714.52€ and uncontrolled asthma 1047.86€ . Hospitalizations, physician vis-
its, diagnostic tests, co morbid diseases costs and medication costs estimated 4 %, 
21%, 7%, 27%, 40% of total costs for controlled patient, 27%, 16%, 5%, 21%, 31% of 
total costs for partial controlled patient and 50%, 11%, 4%, 14%, 21% for uncontrolled 
patient respectively. ConClusions: The direct cost of pediatric asthma in Turkey 
increases depending on disease control level along with different spectrum of item 
distributions. To increase the utility and effectiveness of health care system, the 
findings of this evaluation may guide to construct future policies.
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objeCtives: Pulmonary arterial hypertension (PAH) is a rare disease, for which only 
scarce health care cost data is available in Europe. The progressive nature of the 
disease often requires hospitalization, the costs of which are currently unknown 
in Belgium, mainly due to the low number of patients affected. The objective of 
this research was to assess the cost and length of stay (LOS) of a PAH-related hos-
pitalization likely related to disease worsening in Belgium. Methods: A retro-
spective database analysis was performed using the IMS hospital disease database 
from 2009 to 2011, covering 20% (2010/2011) to 34% (2009) of the hospital beds in 
Belgium. Data on adult patients, who were either hospitalized with a primary 
diagnosis of primary pulmonary hypertension (PH) (ICD-9-CM code 416.0) OR were 
receiving ≥ 1 medication indicated for PAH, was extracted. To ensure hospitaliza-
tions were likely related to disease worsening and not to planned procedures or 
routine visits, only unscheduled hospitalizations of at least 2 days were included 
in the analysis. Hospitalizations were excluded if primary co-diagnoses were sug-
gestive of a non-PAH-related reason for the admission. Total hospitalization costs, 
including hotel, drugs, procedure costs (extrapolated to 2013), and length of stay 
(LOS) were analyzed with descriptive statistics. Results: 35 hospitalizations were 
included into the study. Patients experiencing these admissions were mainly female 
(71.4%), which is in line with the known female-male ratio (2-1) for this rare dis-
ease. Mean (SD) hospitalization cost was € 20,229 (9,399), including € 4,396 (9,502) 
drug, € 8,499 (8,999) hotel, and € 7,334 (12,386) procedure costs. Average LOS was 
17.7±16.8 days. ConClusions: Long durations and high incurred costs for PAH-
related hospitalizations reveal the severe morbidity, health care, and patient burden 
of PAH in Belgium.
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objeCtives: Community-acquired pneumonia (CAP) represents a considerable bur-
den in Russia. We assessed cost of CAP in Russia to characterize disease burden in 
Russian adults of age 50 and older. Methods: We conducted a retrospective chart 
review in a central Russian region of Tver for samples of 900 patients treated in inpa-
tient and outpatient settings, and extrapolated data nationally. All patients were 50 
years of age and represented new cases of CAP. Data were collected on demograph-
ics, comorbidities, and employment. The cost was estimated from the public payer 
perspective, with a productivity loss in patients below retirement age. Results: 
Cost of treatment was similar across age-and-risk groups in hospital and in outpa-
tient settings. The cost of an outpatient episode was estimated far all risk groups at 
RR2176 ($69), ranging from RR1,939 ($61) to RR2537 (~$80) for age groups 50-64 and 
75-84 respectively; the cost of episode for low-risk patients was RR1737 ($55), and 
